OREANDA-NEWS. The American Independent Data and Safety Monitoring Board (DSMB) is worried that the pharmaceutical company AstraZeneca could give partial and irrelevant data on the value of their coronavirus vaccine which could be based on the results of the outdated study. This is stated in a review of the US National Institute of Allergy and Infectious Diseases (NIAID).

On March 22, AstraZeneca informed that their tests in some countries - the United States, Chile and Peru - demonstrated 79% effectiveness of their drug against symptomatic coronavirus and 100% against its severe form. The company also emphasized that the independent research group did not reveal any high risk of thrombosis among those who got their vaccine. The drug was well coped with, according to representatives of AstraZeneca.

DSMB informed NIAID, the Advanced Biomedical Research and Development Administration (BARDA) and AstraZeneca itself on March 22, that it was "worried about the data published by AstraZeneca about the initial clinical trial data for its COVID-19 vaccine."

The NIAID said that "DSMB expressed worrying that AstraZeneca may have give outdated information from the tests, which could form an incomplete picture of the drug's efficiency."

The institute asked AstraZeneca to partner with the American Independent Council for Data and Safety Monitoring closer and "release the most relevant and up-to-date test results on their vaccine use."